Zobrazeno 1 - 10
of 85
pro vyhledávání: '"Yee Chao"'
Autor:
Li-Tzong Chen, Taroh Satoh, Keisho Chin, Takaki Yoshikawa, Yee Chao, Masahiro Tsuda, Hyun Cheol Chung, Keun Wook Lee, Keiko Minashi, Min Hee Ryu, Jong Gwang Kim, Yoon-Koo Kang, Jae Yong Cho, Ken Kato, Narikazu Boku, Won Ki Kang, Takao Tamura, Do Youn Oh, Kun-Huei Yeh, Li Yuan Bai, Yasuo Hamamoto, Taihei Nishiyama, Jen-Shi Chen, Kei Muro, Sang Cheul Oh
Publikováno v:
Gastric Cancer
Background ATTRACTION-2 demonstrated that nivolumab improved overall survival (OS) vs placebo in patients with advanced gastric cancer treated with ≥ 2 chemotherapy regimens. However, its long-term efficacy and outcome of treatment beyond progressi
Autor:
Philip J. Gold, Jan K Davidson-Moncada, Keun-Wook Lee, Yeul Hong Kim, Jon M. Wigginton, Minori Koshiji Rosales, Se Hoon Park, Rosalyn A. Juergens, Haeseong Park, Hope E. Uronis, Cheng Ean Chee, Yee Chao, Daniel V.T. Catenacci, Aleksandra Franovic, Yoon-Koo Kang, Jeffrey L. Nordstrom, Kristen A. Marrone, Eun-Kee Song, Jill Lacy, Sunnie Kim, Johanna C. Bendell, Sang Cheul Oh, Matthew C.H. Ng, Ronan J. Kelly, Jennifer Yen, Jong Gwang Kim, Keith L. Knutson, Yung-Jue Bang, A. Craig Lockhart, Howard S. Hochster, Daner Li, Thierry Alcindor, Sun Jin Sym, Peter C. Enzinger
Publikováno v:
The Lancet Oncology. 21:1066-1076
Summary Background Margetuximab, a novel, investigational, Fc-engineered, anti-HER2 monoclonal antibody, is designed to more effectively potentiate innate immunity than trastuzumab. We aimed to evaluate the safety, tolerability, and antitumour activi
Autor:
Yee Chao, Siddharth Sheth, Judson M. Englert, Yung-Jue Bang, Michael K. Gibson, Cheng Ean Chee, Ronan J. Kelly, Hyun Cheol Chung, Zev A. Wainberg, Jeeyun Lee, Peng He, Johanna C. Bendell, Rom Leidner, Philip Z Brohawn, Jennifer McDevitt, Mariela Blum-Murphy, Keun Wook Lee, Takeshi Omori, Heinz-Josef Lenz, Geoffrey Y. Ku, Crystal S. Denlinger, Daniel V.T. Catenacci, Marlon Rebelatto, Khaldoun Almhanna
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 26, iss 4
Clin Cancer Res
Clin Cancer Res
Purpose: This randomized, multicenter, open-label, phase Ib/II study assessed durvalumab and tremelimumab in combination or as monotherapy for chemotherapy-refractory gastric cancer or gastroesophageal junction (GEJ) cancer. Patients and Methods: Sec
The clinicopathological characteristics and genetic alterations of mucinous carcinoma of the stomach
Autor:
Chien Hsun Tseng, Chew Wun Wu, Kuo Hung Huang, Yee Chao, Su Shun Lo, Wen Liang Fang, Anna Fen Yau Li, Yi Ming Shyr, Ming Huang Chen
Publikováno v:
Journal of the Chinese Medical Association. 83:141-147
Background Mucinous gastric carcinoma (MGC) is rare and often associated with an advanced stage. The clinicopathological features and prognosis of MGC and non-MGC (NMGC) are controversial. Methods In total, 2637 gastric cancer (GC) patients receiving
Autor:
Yee Chao, Huanyu Zhao, Chiun Hsu, Ryoko Kuromatsu, Jeffrey Anderson, Winnie Yeo, Christine Dela Cruz, Ming-Mo Hou, Akhil Chopra, Tae You Kim, Michihisa Moriguchi, Yoon-Koo Kang, Su Pin Choo, Masafumi Ikeda, Thomas Yau, Kazushi Numata, Masatoshi Kudo
Publikováno v:
Ann Transl Med
Background & Aims Nivolumab, an immune checkpoint inhibitor, is approved in several countries to treat sorafenib-experienced patients with HCC, based on results from the CheckMate 040 study (NCT01658878). Marked differences exist in HCC clinical pres
Autor:
Hou Hsuan Cheng, Jeng Kai Jiang, Shih Ching Chang, Wei Shone Chen, Huann Sheng Wang, Shung Haur Yang, Yee Chao, Tsai Sheng Yang, Chun Chi Lin, Yuan Tzu Lan, Chien Chih Chen, Hung Hsin Lin, Kuo Cheng Huang, Hung Chih Hsu, Hao Wei Teng, Sheng Chieh Huang
Publikováno v:
Scientific Reports
Scientific Reports, Vol 11, Iss 1, Pp 1-13 (2021)
Scientific Reports, Vol 11, Iss 1, Pp 1-13 (2021)
Given the unclear preference criteria for regorafenib in treating refractory metastatic colorectal cancer (mCRC), this study aimed to construct an algorithm in selecting right patients for regorafenib. This was a multicenter retrospective cohort stud
Autor:
Yu-Mei Kang, Yi-Yen Lee, Shih-Chieh Lin, Feng-Chi Chang, Sanford P. C. Hsu, Chun-Fu Lin, Muh-Lii Liang, Hsin-Hung Chen, Tai-Tong Wong, Keng-Li Lan, Yee Chao, Yi-Wei Chen
Publikováno v:
PLOS ONE. 17:e0264641
Intracranial germinoma (IG) rarely occurs in adults. Its optimal treatment strategy is unclear. We evaluated the outcomes of radiotherapy in adults with intracranial germinoma. Data of 29 adult patients (age, 18–52 years; median age, 24.3 years) wi
Autor:
Chia Jui Yen, Yee Chao, Wichit Arpornwirat, Joshua Tobias, Marina Maglakelidze, Jedzada Maneechavakajorn, Thomas Yau, Mirjana Drinić, Iurie Bulat, Nicholas J. Ede, Teerapat Ungtrakul, Chaiyut Charoentum, Suebpong Tanasanvimon, Wen-Chi Chou, Aumkhae Sookprasert, Li Yuan Bai, Erika Garner-Spitzer, Arunee Dechaphunkul, Anthony J Good, Leslie Chong, Mark T. Marino, Ursula Wiedermann, Christoph C. Zielinski
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 27(13)
Purpose: HER2/neu is overexpressed in up to 30% of gastroesophageal adenocarcinomas (GEA) and linked to poor prognosis. Recombinant mAbs to treat HER2/neu-overexpressing cancers are effective with limitations, including resistance and toxicity. There
Autor:
Yee Chao, Chih Yean Lum, Chew Wun Wu, Kuo Hung Huang, Yi Ming Shyr, Ming Huang Chen, Wen Liang Fang, Anna Fen Yau Li, Su Shun Lo
Publikováno v:
Journal of the Chinese Medical Association : JCMA. 83(8)
BACKGROUND Lymph node (LN) metastasis is one of the independent prognostic factors of gastric cancer (GC). The difference in survival rates and initial recurrence patterns in patients with node-positive GC with retrieved LN numbers greater than or le
Autor:
Liang Liang, Kyung Hun Lee, Yee Chao, Jong Seok Lee, Chia Jui Yen, Yun Zhang, Chia-Chi Lin, Chang Hsien Lu, Michael B. Jameson, Andrew G. Hill, Ben Markman, Shahneen Sandhu, Virginia E. Paton, Michael Friedlander, John Wu, Yoon-Koo Kang, Kun Ming Rau, Ming Mo Hou, Bhumsuk Keam, Chi Yuan Wu, Jayesh Desai, Michael Millward, Lisa G. Horvath, Sanjeev Deva, Paula Barlow
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
BackgroundThe programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1) axis plays a central role in suppressing antitumor immunity; axis dysregulation can be used by cancer cells to evade the immune system. Tislelizumab, an investigational